Literature DB >> 26839141

The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer.

Benjamin T Ristau1, David Cahn2, Robert G Uzzo1, Brian F Chapin3, Marc C Smaldone1.   

Abstract

A lack of quality evidence comparing management strategies confounds complex treatment decisions for patients with high-risk prostate cancers. No randomized trial comparing surgery to radiation has been successfully completed. Despite inherent selection biases, however, observational and registry data suggest improved outcomes for patients initially managed with prostatectomy. As consensus shifts away from aggressive treatment for low-risk disease and toward multimodal treatment of locally advanced and metastatic disease, there is renewed interest in surgery for local control in patients presenting with high-risk localized, node-positive and minimally metastatic disease. The objective of this review is to examine the evidence evaluating clinical outcomes of patients with high-risk clinically localized, node-positive and metastatic prostate cancer treated with radical prostatectomy.

Entities:  

Keywords:  cytoreductive surgery; outcomes; prostate cancer; radical prostatectomy

Mesh:

Year:  2016        PMID: 26839141     DOI: 10.2217/fon.15.355

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

1.  A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.

Authors:  Matthew J O'Shaughnessy; Sean M McBride; Hebert Alberto Vargas; Karim A Touijer; Michael J Morris; Daniel C Danila; Vincent P Laudone; Bernard H Bochner; Joel Sheinfeld; Erica S Dayan; Lawrence P Bellomo; Daniel D Sjoberg; Glenn Heller; Michael J Zelefsky; James A Eastham; Peter T Scardino; Howard I Scher
Journal:  Urology       Date:  2016-11-22       Impact factor: 2.649

2.  Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates.

Authors:  Muammer Altok; Patricia Troncoso; Mary F Achim; Surena F Matin; Graciela N Gonzalez; John W Davis
Journal:  Asian J Androl       Date:  2019 Nov-Dec       Impact factor: 3.285

3.  Difference of opinion - Radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: No.

Authors:  Benjamin T Ristau; Marc C Smaldone
Journal:  Int Braz J Urol       Date:  2016 Sep-Oct       Impact factor: 1.541

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.